Results 291 to 300 of about 221,285 (352)

Prognostic value of NT‐proBNP in patients with primary mitral regurgitation undergoing transcatheter edge‐to‐edge repair

open access: yesEuropean Journal of Heart Failure, EarlyView.
In the PRIME‐MR study, patients with higher N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) tertiles more frequently reached death or heart failure hospitalization (HFH) within 3 years. Log‐transformed NT‐proBNP levels independently predicted the primary endpoint (adjusted hazard ratio 1.17, 95% confidence interval 1.07–1.28; p < 0.001).
Philipp von Stein   +70 more
wiley   +1 more source

Sex‐based differences in heart failure management and outcomes: Insights from the French‐DataHF cohort

open access: yesEuropean Journal of Heart Failure, EarlyView.
Sex differences in heart failure (HF) management and outcomes in the French‐DataHF cohort. CI, confidence interval; HFH, heart failure hospitalization; HR, hazard ratio; IPW, inverse probability weighting; KM, Kaplan–Meier; LD, loop diuretic; RAS, renin–angiotensin system; RASi, renin–angiotensin system inhibitor.
Guillaume Baudry   +7 more
wiley   +1 more source

High sensitivity C-reactive protein subsequent rise in urine albumin/creatinine ratio/fall in estimated glomerular filtration rate over 24 years in people with type 2 diabetes. [PDF]

open access: yesCardiovasc Endocrinol Metab
Veulchamy S   +11 more
europepmc   +1 more source

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR‐HF2 DZHK05 trial): Sex‐specific outcomes

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Intravenous iron has emerged as a guideline‐recommended therapy in patients with heart failure and iron deficiency, but the potential sex‐related differences in efficacy are unknown. We aimed to assess sex‐specific outcomes in the Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
Mahir Karakas   +49 more
wiley   +1 more source

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study

open access: yes
European Journal of Heart Failure, EarlyView.
Stephen J. Greene   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy